Somatostatin receptor imaging and theranostics: Current practice and future prospects

Sonya Park, Ashwin Singh Parihar, Lisa Bodei, Thomas A. Hope, Nadine Mallak, Corina Millo, Kalpna Prasad, Don Wilson, Katherine Zukotynski, Erik Mittra

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

A new era of precision diagnostics and therapy for patients with neuroendocrine neoplasms began with the approval of somatostatin receptor (SSTR) radiopharmaceuticals for PET imaging followed by peptide receptor radionuclide therapy (PRRT). With the transition from SSTR-based g-scintigraphy to PET, the higher sensitivity of the latter raised questions regarding the direct application of the planar scintigraphy–based Krenning score for PRRT eligibility. Also, to date, the role of SSTR PET in response assessment and predicting outcome remains under evaluation. In this comprehensive review article, we discuss the current role of SSTR PET in all aspects of neuroendocrine neoplasms, including its relation to conventional imaging, selection of patients for PRRT, and the current understanding of SSTR PET–based response assessment. We also provide a standardized reporting template for SSTR PET with a brief discussion.

Original languageEnglish (US)
Pages (from-to)1323-1329
Number of pages7
JournalJournal of Nuclear Medicine
Volume62
Issue number10
DOIs
StatePublished - Oct 1 2021

Keywords

  • Ga-DOTANOC
  • Ga-DOTATATE
  • Neuroendocrine neoplasms
  • Peptide receptor radionuclide therapy
  • Somatostatin
  • SSTR

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of 'Somatostatin receptor imaging and theranostics: Current practice and future prospects'. Together they form a unique fingerprint.

Cite this